Skip to content

Genesis Energy

US · GEL #2897 by market cap Listed 1970
14.32 +0.04 +0.28%
Live - 5344 symbols - heartbeat 139s ago · 2026-10-08 07:37
Pre-market 14.32 0.00%
After-hours 14.32 0.00%
Market cap
1.75B
P/B
-149.17
EPS
-4.19
Reader sentiment Are you bullish or bearish on GEL?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    Wells Fargo Initiates Genesis Energy(GEL.US) With Buy Rating, Announces Target Price $18
    Market Newswire · 2026/8/14
  • Rating change
    Mizuho Securities Initiates Sol-Gel Technologies(SLGL.US) With Buy Rating, Announces Target Price $285
    Market Newswire · 2026/6/24
  • Beiteli (301697.SZ): Thermal conductive gel samples have been delivered to leading optical module clients, but sales have not yet commenced.
    Gelonghui Finance · 2026/9/7
  • Company notice
    Sol-Gel Technologies | 4: Statement of changes in beneficial ownership of securities-10% Owner Opaleye Management Inc.
    SEC · 2026/9/4
  • Rating change
    LifeSci Capital Maintains Sol-Gel Technologies(SLGL.US) With Buy Rating, Maintains Target Price $184
    Market Newswire · 2026/8/18
  • Beiteli (301697.SZ): Its thermal conductive gel products are applicable to the data center sector and are currently in the sample testing phase.
    Gelonghui Finance · 2026/9/7
  • Rating change
    LifeSci Capital Initiates Sol-Gel Technologies(SLGL.US) With Buy Rating, Announces Target Price $184
    Market Newswire · 2026/5/15
  • Company notice
    C'BON COSMETICS: Both the Sea and the bright impression. With W ingredient* and W concentration*, the targeted, rich gel serum "Seeboon AC W Shot Serum" has arrived.
    JPX · 2026/9/24
  • Rating change
    H.C. Wainwright Maintains Sol-Gel Technologies(SLGL.US) With Buy Rating, Maintains Target Price $110
    Market Newswire · 2026/7/20
  • Rating change
    Wells Fargo Maintains Genesis Energy(GEL.US) With Buy Rating, Cuts Target Price to $18
    Market Newswire · 2026/5/13
  • Mizuho Securities Maintains Sol-Gel Technologies(SLGL.US) With Buy Rating, Maintains Target Price $285
    Market Newswire · 2026/8/21
  • Palvella Therapeutics Receives Third Year Of Grant Funding From FDA Office Of Orphan Products Development For Phase 3 SELVA Trial And Ongoing Open-Label Extension Study Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Microcystic Lymphatic...
    Benzinga · 2026/9/28
  • Company notice
    Sol-Gel Technologies | 4: Statement of changes in beneficial ownership of securities-10% Owner Opaleye Management Inc.
    SEC · 2026/9/10
  • Rating change
    TD Cowen Initiates Sol-Gel Technologies(SLGL.US) With Buy Rating
    Market Newswire · 2026/5/29
  • LifeSci Capital Maintains Sol-Gel Technologies(SLGL.US) With Buy Rating, Maintains Target Price $195
    Market Newswire · 2026/8/23
  • Rating change
    RBC Capital Maintains Genesis Energy(GEL.US) With Buy Rating, Cuts Target Price to $18
    Market Newswire · 2026/7/22
  • Company notice
    Kowa: Regarding the sale of walking aids equipped with "αGEL" material grips, under a partnership with Taika Co., Ltd.
    JPX · 2026/9/14
  • Rating change
    LifeSci Capital Maintains Sol-Gel Technologies(SLGL.US) With Buy Rating, Raises Target Price to $195
    Market Newswire · 2026/8/20
  • Rating change
    HC Wainwright & Co. Reiterates Buy on Sol-Gel Technologies, Maintains $110 Price Target
    Benzinga · 2026/7/20
  • Company notice
    Sol-Gel Technologies | 4: Statement of changes in beneficial ownership of securities-10% Owner Opaleye Management Inc.
    SEC · 2026/9/15

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 07:37:42 · For reference only, not investment advice and not tailored to your situation.